Recently, fixed low-dose capecitabine (1,000 mg b.i.d.), administered continuously, has been administered to patients with gastrointestinal cancers with a high level of safety. Capecitabine 1,000 mg twice daily without interruption was used for the first 11 patients. The dose was reduced to 1,000 mg twice daily 5 days per week in 8 patients who developed hand-foot syndrome. Main toxicities were grade 1 to 2 fatigue and hand-foot syndrome.